
Novo Nordisk said on Wednesday that it would axe 9,000 jobs as it lowered its profit guidance for the third time this year.
The Danish pharmaceutical giant pointed to fierce competition in the obesity drug market, hitting its weight-loss products Ozempic and Wegovy.